Actively Recruiting
Bleeding In Thrombocytopenia Explained
Led by Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research · Updated on 2023-12-21
1000
Participants Needed
1
Research Sites
390 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Multicenter case cohort study investigating clinical risk factors for clinically relevant bleeding in hemato-oncology patients, as well as bleeding related biomarkers during intensive treatment.
CONDITIONS
Official Title
Bleeding In Thrombocytopenia Explained
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Hospital admission (part A and B)
- Age 18 years or older (part A and B)
- Hemato-oncology patient, including MDS and aplastic anemia, admitted for treatment (chemotherapy, stem cell transplantation) with expected thrombocytopenia (platelet count < 50 x10^9/L for at least 5 days) and possible prophylactic platelet transfusions (part A and B)
- OR hemato-oncology patient previously treated with intensive chemotherapy or stem cell transplantation, admitted for disease- or treatment-related events or complications (part A only)
You will not qualify if you...
- Diagnosis of myeloproliferative disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
LUMC
Leiden, South Holland, Netherlands, 2333 ZA
Actively Recruiting
Research Team
L
Loes Cornelissen, MD, PhD student
CONTACT
R
Rutger Middelburg, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here